UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 263,905 shares of the biopharmaceutical company's stock after acquiring an additional 27,683 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.22% of Catalyst Pharmaceuticals worth $5,508,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC lifted its stake in shares of Catalyst Pharmaceuticals by 129.4% in the third quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company's stock valued at $4,939,000 after buying an additional 140,129 shares in the last quarter. KBC Group NV raised its stake in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,542 shares during the last quarter. Spire Wealth Management lifted its holdings in shares of Catalyst Pharmaceuticals by 1,342.9% in the fourth quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock valued at $301,000 after purchasing an additional 13,429 shares in the last quarter. abrdn plc purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $10,115,000. Finally, Meritage Portfolio Management grew its holdings in Catalyst Pharmaceuticals by 7.4% during the fourth quarter. Meritage Portfolio Management now owns 46,090 shares of the biopharmaceutical company's stock worth $962,000 after buying an additional 3,176 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at $1,627,468.99. This trade represents a 38.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CPRX shares. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Finally, Stephens reiterated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $32.29.

Catalyst Pharmaceuticals Stock Performance

CPRX traded down $0.03 during midday trading on Thursday, reaching $25.26. The company had a trading volume of 563,930 shares, compared to its average volume of 1,110,736. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.75 and a 12-month high of $26.16. The business has a 50-day moving average price of $23.58 and a two-hundred day moving average price of $22.68. The stock has a market cap of $3.08 billion, a PE ratio of 21.38, a P/E/G ratio of 3.31 and a beta of 0.70.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.